Branca Bunus

Executive Summary

Branca Bunus is an early-stage Irish gene therapy company developing next-generation non-viral gene delivery vectors based on its proprietary HPAE polymer platform. Founded in 2020, the company aims to address key limitations of viral vectors and existing transfection reagents by offering high-performance, scalable, and cost-effective alternatives. Its lead product, BrPERfect®, is positioned as a transfection reagent for research and biomanufacturing applications, targeting the growing market for viral vector and protein production. The HPAE platform could potentially enable more efficient and safer gene therapies across a range of indications. As a private, pre-revenue company with minimal public information, Branca Bunus faces typical early-stage risks but benefits from increasing demand for non-viral delivery technologies. Its success hinges on demonstrating reproducible performance, securing funding for scale-up, and establishing partnerships with biopharma or contract development organizations. The company operates in Dublin, Ireland, within a supportive biotech ecosystem.

Upcoming Catalysts (preview)

• Q4 2026Series A Funding Round60% success
• Q1 2027Partnership with Biomanufacturing CDMO40% success
• Q3 2026Publication of Preclinical Data on BrPERfect®70% success